An Updated Analysis Evaluating Skeletal Related Events (sres) in CTRIAL-IE 13-21: Phase II Trial of Radium-223 (R223) in Combination with Enzalutamide (ENZA) for Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined